Mereo BioPharma Group plcMREOEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Mereo BioPharma Group plc is a UK-based clinical-stage biopharmaceutical company that develops targeted innovative therapies for rare diseases, oncology, and severe chronic conditions. It operates primarily across European and North American markets, advancing multiple late-stage pipeline candidates to address unmet patient medical needs.
MREO Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-10.0M
Net Profit
$-7.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.01
Mereo BioPharma Group plc Q3 FY2025 Financial Summary
Mereo BioPharma Group plc reported revenue of $0 for Q3 FY2025, with a net profit of $-7.0M (up 53.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Mereo BioPharma Group plc Quarterly Revenue & Net Profit History
Mereo BioPharma Group plc results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-7.0M | N/A |
| Q3 FY2024 | $0 | — | $-15.0M | N/A |
| Q2 FY2024 | $0 | — | $-12.3M | N/A |
| Q1 FY2024 | $0 | — | $-9.0M | N/A |
| Q2 FY2023 | $9.0M | — | $-1.8M | -19.5% |
| Q1 FY2023 | $0 | — | $-12.1M | N/A |
Income Statement
| Q1 2023 | Q2 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $9.0M | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2023 | Q2 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | N/A | N/A | $55.9M | $96.1M | $88.7M | $53.6M |
| Liabilities | N/A | N/A | $13.1M | $17.5M | $16.2M | $7.0M |
| Equity | $44.4M | $49.7M | $42.8M | $78.7M | $-72.5M | $46.6M |
Cash Flow
| Q1 2023 | Q2 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-9.2M | $-7.8M | $-8.0M | $-7.9M | $-7.5M | $-7.3M |